There are currently 64 clinical trials in Doral, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Universal Axon Clinical Research, Integrity Clinical Research, LLC, Prohealth Research Center and Moonshine Research Center, Inc.. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)
Recruiting
This study of the efficacy and safety of Plecanatide in children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C)
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/06/2023
Locations: Synergy Research Site, Doral, Florida
Conditions: Irritable Bowel Syndrome With Constipation
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
Recruiting
Study of EDP-235 in Non-hospitalized Adults with Mild or Moderate COVID-19.
Gender:
All
Ages:
Between 18 years and 64 years
Trial Updated:
12/06/2022
Locations: Doral Medical Research, Doral, Florida
Conditions: COVID-19
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
Recruiting
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
Gender:
All
Ages:
18 years and above
Trial Updated:
09/08/2022
Locations: Prohealth Research Center, Doral, Florida +1 locations
Conditions: Covid19
Study to Evaluate Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2022
Locations: Universal Axon Clinical Research, Doral, Florida
Conditions: Heart Failure, Reduced Ejection Fraction